                                  DC REGULATIONS

SPECIALITY SERVICES &#8212; ADDITIONAL STANDARDS FOR NARCOTIC TREATMENT (OPIOID
REPLACEMENT) PROGRAMS (§ 29-2361)

2361.1. In addition to the requirements of this section, programs providing
   narcotic treatment shall comply with standards for all facilities and program
   as specified in this chapter.

   2361.2. Substance abuse treatment facilities or programs providing narcotic
   treatment with opioid replacement therapy shall comply with federal
   requirements for opioid treatment as specified in 21 C.F.R. Part 291 and shall
   comply with District and federal regulations for maintaining controlled
   substances as specified in Chapter 10, Title 22 of the District of Columbia
   Municipal Regulations, and 21 C.F.R. Part 1300, respectively.

   2361.3. Each narcotic treatment program or service delivery site, whether
   providing inpatient or outpatient services shall submit applications to the
   Department and the U.S. Food and Drug Administration (FDA), respectively and
   shall require the approval of both agencies prior to its initial operation.

   2361.4. A narcotic treatment program shall submit to the Department
   photocopies of all applications, reports and notifications required by federal
   laws and regulations.

   2361.5. Narcotic treatment programs shall ensure the following:
   
   
   
   (a)	Access to electronic alarm areas where drug stock is maintained shall be
   limited to a minimum number of authorized licensed personnel. Each employee
   shall have his/her own individual code, which shall be erased upon
   termination.
   
   
   
   (b)	All stored drugs (liquid, powder, solid and reconstituted) including
   controlled substances, shall be clearly labeled with the following
   information:
   
   
   
   (1)	Name of substance;
   
   
   
   (2)	Strength of substance;
   
   
   
   (3)	Date of reconstitution or preparation;
   
   
   
   (4)	Manufacturer and lot number;
   
   
   
   (5)	Manufacturer’s expiration date; or
   
   
   
   (6)	Reconstituted/prepared drug’s expiration date according to the
   manufacturer’s expiration date, or one (1) year from the date of
   reconstitution or preparation, whichever is shorter.
   
   
   
   (c)	Take-home medications shall be labeled and packaged in accordance with
   Federal and District laws and shall include the following information:
   
   
   
   (1)	Treatment program’s name, address, and telephone number;
   
   
   
   (2)	Physician’s name;
   
   
   
   (3)	Patient’s name;
   
   
   
   (4)	Directions for ingestion;
   
   
   
   (5)	Name of medication;
   
   
   
   (6)	Dosage in milligrams;
   
   
   
   (7)	Date issued; and
   
   
   
   (8)	Cautionary labels as appropriate;

   2361.6. Containers of drugs shall be kept covered and stored in the
   appropriate locked safe with access limited by an electronic alarm system that
   conforms to DEA and District requirements.

   2361.7. The Department shall be notified of any theft, suspected theft or any
   significant loss of controlled substances, including spillage. Photocopies of
   DEA forms 106 and 41 shall be submitted to the Department.
   
   
   
   	SOURCE: Final Rulemaking published at 47 DCR 9341 (November 24, 2000),
   adopting Emergency and Proposed Rulemaking published at 47 DCR 7708, 7798
   (September 22, 2000).
